Fairmount Funds Management’s Iovance Biotherapeutics IOVA Stock Holding History

Fairmount Funds Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-389,588	Closed	-$3.73M	–	23
2022 Q3	$3.73M	Hold	389,588	–	–	0.66%	24
2022 Q2	$4.3M	Hold	389,588	–	–	0.98%	23
2022 Q1	$6.49M	Hold	389,588	–	–	1.53%	18
2021 Q4	$7.44M	Hold	389,588	–	–	2.45%	16
2021 Q3	$9.61M	Sell	389,588 -116,302	-23%	-$2.74M	3.49%	12
2021 Q2	$13.2M	Sell	505,890 -60,000	-11%	-$1.56M	5.41%	5
2021 Q1	$17.9M	Hold	565,890	–	–	7.55%	3
2020 Q4	$26.3M	Sell	565,890 -31,000	-5%	-$1.23M	9.39%	3
2020 Q3	$19.6M	Sell	596,890 -7,000	-1%	-$215K	8.32%	5
2020 Q2	$16.6M	Buy	603,890 +112,500	+23%	+$3.7M	7.39%	6
2020 Q1	$14.7M	Buy	491,390 +37,500	+8%	+$994K	8.92%	4
2019 Q4	$12.6M	Buy	+453,890	New	+$10.3M	7.62%	5

Other funds holding IOVA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fairmount Funds Management's IOVA Position: Q4 2022 in Review

Fairmount Funds Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 389,588 shares — an estimated $3.73M sold.

Fairmount Funds Management first reported a position in IOVA in Q4 2019 and held it in 12 quarters. The position peaked at $26.3M in Q4 2020. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Fairmount Funds Management reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Fairmount Funds Management sold 389,588 Iovance Biotherapeutics shares in Q4 2022, an estimated $3.73M.
Fairmount Funds Management first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 12 quarters.
Fairmount Funds Management's Iovance Biotherapeutics position peaked at $26.3M in Q4 2020.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.